期刊
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
卷 39, 期 4, 页码 478-487出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00005344-200204000-00003
关键词
ACE-inhibition; angiotensin-(1-7); ATI receptor blockade; bradykinin; kallikrein-kinin system; renin-angiotensin system
The investigation of therapeutic actions of angiotensin type I (AT1) receptor antagonists and ACE inhibitors (ACEI) demonstrated complex interactions between the renin-angiotensin system (RAS) and the kallikreinkinin system (KKS) in several experimental and clinical studies. They are evidenced by the fact that (1) ACE efficiently catabolizes kinins; (2) angiotensin-derivatives such as ANG-(1-7) exert kininlike effects; and (3) kallikrein probably serves as a prorenin-activating enzyme. (4) Several authors have demonstrated experimentally that the protective effects of ACEI are at least partly mediated by a direct potentiation of kinin receptor response on B K stimulation. (5) Furthermore, studies on ATI antagonists, which do not directly influence kinin degradation, and studies on angiotensin-receptor transgenic mice have revealed additional interactions between the RAS and the KKS. There is mounting evidence that an autocrine cascade including kinins. nitric oxide, prostaglandins, and cyclic GMP is involved in at least some of the angiotensin type 2 receptor effects. This review discusses multiple possibilities of cross-talks between the RAS and KKS in vascular and cardiac physiology and pathology after ACE inhibition and AT1 receptor blockade.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据